Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 940 participants.

Also called NCT06187311

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 940 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06187311
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06187311. Randomized; no masking; primary purpose treatment. Start 2023-01-12 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
Acronym
REVISE-AF
Condition
Anticoagulant Adverse Reaction
Intervention (Drug)
Rivaroxaban 20 MG
Intervention (Drug)
Rivaroxaban 15 MG
Lead sponsor
Korea University Anam Hospital (class: other)

Record details

Record id
cardio:ct-nct06187311
Content hash
3607e6ac854b2ec2ab9a906150471ec7e31b1819a09ea697cf96f0f80683aff3